Pub. Date : 2020 Apr 30
PMID : 32142738
16 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | Disulfiram (DSF) is an inhibitor of P-glycoprotein (Pgp), the main obstacle limiting the success of doxorubicin (DOX), but it has poor solubility and stability. | Doxorubicin | ATP binding cassette subfamily B member 1 | Homo sapiens |
| 2 | Disulfiram (DSF) is an inhibitor of P-glycoprotein (Pgp), the main obstacle limiting the success of doxorubicin (DOX), but it has poor solubility and stability. | Doxorubicin | ATP binding cassette subfamily B member 1 | Homo sapiens |
| 3 | Disulfiram (DSF) is an inhibitor of P-glycoprotein (Pgp), the main obstacle limiting the success of doxorubicin (DOX), but it has poor solubility and stability. | Doxorubicin | ATP binding cassette subfamily B member 1 | Homo sapiens |
| 4 | Disulfiram (DSF) is an inhibitor of P-glycoprotein (Pgp), the main obstacle limiting the success of doxorubicin (DOX), but it has poor solubility and stability. | Doxorubicin | ATP binding cassette subfamily B member 1 | Homo sapiens |
| 5 | LipoDSF-DOX increased DOX intracellular accumulation and cytotoxicity in Pgp-expressing breast cancer cells, with an efficacy superior to the mixture of free DSF and DOX, thanks to a differential kinetics of release of DSF and DOX when carried by liposomes. | Doxorubicin | ATP binding cassette subfamily B member 1 | Homo sapiens |
| 6 | LipoDSF-DOX increased DOX intracellular accumulation and cytotoxicity in Pgp-expressing breast cancer cells, with an efficacy superior to the mixture of free DSF and DOX, thanks to a differential kinetics of release of DSF and DOX when carried by liposomes. | Doxorubicin | ATP binding cassette subfamily B member 1 | Homo sapiens |
| 7 | LipoDSF-DOX increased DOX intracellular accumulation and cytotoxicity in Pgp-expressing breast cancer cells, with an efficacy superior to the mixture of free DSF and DOX, thanks to a differential kinetics of release of DSF and DOX when carried by liposomes. | Doxorubicin | ATP binding cassette subfamily B member 1 | Homo sapiens |
| 8 | LipoDSF-DOX increased DOX intracellular accumulation and cytotoxicity in Pgp-expressing breast cancer cells, with an efficacy superior to the mixture of free DSF and DOX, thanks to a differential kinetics of release of DSF and DOX when carried by liposomes. | Doxorubicin | ATP binding cassette subfamily B member 1 | Homo sapiens |
| 9 | The mechanism of the increased DOX retention relied on the DSF-induced sulfhydraton of Pgp and followed by its ubiquitination. | Doxorubicin | ATP binding cassette subfamily B member 1 | Homo sapiens |
| 10 | These events reduced Pgp expression and catalytic activity in LipoDSF-DOX-treated cells. | Doxorubicin | ATP binding cassette subfamily B member 1 | Homo sapiens |
| 11 | Our results show that LipoDSF-DOX effectively reversed DOX resistance in Pgp-expressing breast cancer cells, exploiting the temporally different kinetics of release of DSF and DOX, optimized to decrease expression and activity of Pgp. | Doxorubicin | ATP binding cassette subfamily B member 1 | Homo sapiens |
| 12 | Our results show that LipoDSF-DOX effectively reversed DOX resistance in Pgp-expressing breast cancer cells, exploiting the temporally different kinetics of release of DSF and DOX, optimized to decrease expression and activity of Pgp. | Doxorubicin | ATP binding cassette subfamily B member 1 | Homo sapiens |
| 13 | Our results show that LipoDSF-DOX effectively reversed DOX resistance in Pgp-expressing breast cancer cells, exploiting the temporally different kinetics of release of DSF and DOX, optimized to decrease expression and activity of Pgp. | Doxorubicin | ATP binding cassette subfamily B member 1 | Homo sapiens |
| 14 | Our results show that LipoDSF-DOX effectively reversed DOX resistance in Pgp-expressing breast cancer cells, exploiting the temporally different kinetics of release of DSF and DOX, optimized to decrease expression and activity of Pgp. | Doxorubicin | ATP binding cassette subfamily B member 1 | Homo sapiens |
| 15 | Our results show that LipoDSF-DOX effectively reversed DOX resistance in Pgp-expressing breast cancer cells, exploiting the temporally different kinetics of release of DSF and DOX, optimized to decrease expression and activity of Pgp. | Doxorubicin | ATP binding cassette subfamily B member 1 | Homo sapiens |
| 16 | Our results show that LipoDSF-DOX effectively reversed DOX resistance in Pgp-expressing breast cancer cells, exploiting the temporally different kinetics of release of DSF and DOX, optimized to decrease expression and activity of Pgp. | Doxorubicin | ATP binding cassette subfamily B member 1 | Homo sapiens |